CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Analyst Outlook | Discover why analysts remain optimistic about CVRx's long-term prospects, with price targets ranging from $14 to $23, despite short-term challenges. |
Market Expansion | Learn how CVRx is increasing its market presence, with 227 active implanting centers and strategic adjustments to sales territories for optimized growth. |
Financial Pulse | Despite recent revenue shortfalls, CVRx maintains robust gross margins of 83.75% and achieved 30.53% revenue growth over the last twelve months. |
Barostim Breakthrough | Explore CVRx's innovative heart failure treatment, Barostim, and its potential to revolutionize the $3.7 billion HFrEF market with impressive clinical outcomes. |
Metrics to compare | CVRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCVRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.0x | −5.4x | −0.5x | |
PEG Ratio | −0.23 | −0.10 | 0.00 | |
Price / Book | 2.2x | 4.7x | 2.6x | |
Price / LTM Sales | 2.9x | 3.2x | 3.0x | |
Upside (Analyst Target) | 96.2% | 53.7% | 52.4% | |
Fair Value Upside | Unlock | −3.2% | 8.7% | Unlock |